en · de · es · fr · pt
faq-desk.peptides7250.com › Info › Background And Naming Conventions — Background and Details

Background And Naming Conventions — Background and Details

By Editorial Desk · published 2026-05-23 · last reviewed 2026-07-12 · Info

Everything below concerns peptide mapping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

Analytical Measurement And Stability

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Related pages on this site

Analytical Characterization and Storage

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Handling Storage And Analytical Methods

Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.

Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.

Background from the literature

=== Approved drugs === Aripiprazole (Abilify) – dopamine D2 and D3 partial agonist, serotonin 5-HT1A and 5-HT7 receptor partial agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist or inverse agonist, and atypical antipsychotic Risperidone (Risperdal) – dopamine D2 and D3 receptor antagonist, serotonin 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7 receptor antagonist or inverse agonist, α1- and α2-adrenergic receptor antagonist, histamine H1 receptor inverse agonist, and atypical antipsychotic

This alternative method of methylation analysis also uses bisulfite-treated DNA but avoids the need to sequence the area of interest. Instead, primer pairs are designed themselves to be "methylated-specific" by including sequences complementing only unconverted 5-methylcytosines, or, on the converse, "unmethylated-specific", complementing thymines converted from unmethylated cytosines. Methylation is determined by the ability of the specific primer to achieve amplification. This method is particularly useful to interrogate CpG islands with possibly high methylation density, as increased numbers of CpG pairs in the primer increase the specificity of the assay. Placing the CpG pair at the 3'-end of the primer also improves the sensitivity. The initial report using MSP described sufficient sensitivity to detect methylation of 0.1% of alleles. In general, MSP and its related protocols are considered to be the most sensitive when interrogating the methylation status at a specific locus. The MethyLight method is based on MSP, but provides a quantitative analysis using quantitative PCR. Methylated-specific primers are used, and a methylated-specific fluorescence reporter probe is also used that anneals to the amplified region. In alternative fashion, the primers or probe can be designed without methylation specificity if discrimination is needed between the CpG pairs within the involved sequences. Quantitation is made in reference to a methylated reference DNA.

Drug content Release of medicament from base Medicament penetration Consistency of the preparation Absorption of medicament into blood stream Irritant effect Properties which affect choice of an ointment base are:

Sources: en.wikipedia.org

Reference notes

On 14 June, Canadian prime minister Carney and British prime minister Starmer held their bilateral meeting in Ottawa. On route to Ottawa, Starmer stated that "Canada is an independent, sovereign country and a much-valued member of the Commonwealth" in the wake of President Trump's threats to annex Canada as the 51st state. Upon arrival, Starmer had dinner with Canadian prime minister Mark Carney at his official residence at Rideau Cottage, later the two watched a National Hockey League game between the Edmonton Oilers and Florida Panthers. They agreed to establish an Economic and Trade Working Group and to deepen the Trade Continuity Agreement, while Carney committed Canada to ratifying the UK's accession to CPTPP. The meeting was the first between two international leaders since Israel's strikes on Iran starting the 2025 Iran–Israel conflict; Starmer began a diplomatic push to try to de-escalate the Middle Eastern crisis.

== Hazards == There are hazards involved with being a diener. There are approximately six types of hazards that a diener is at risk for: mechanical, sharp force, electrical, chemical, radiation, and infection. Mechanical hazards categorize harm such as back injury from activity such as transporting cadavers. Sharp force hazards categorize any bodily harm from the use of tools and equipment such as scalpels and needles which resulting in cuts or punctures. Electrical hazards encompass any potential harm in the form of shock from the use of equipment like saws or defibrillators. Chemical hazards include harm from the use of a variety of chemicals used in the autopsy process such as cyanide and formaldehyde. Radiation hazards are related to any exposure from performing x-rays. Infection hazards are due to the potential that a cadaver is infected with a communicable disease.

=== Origins === The first investigative radiochemical measurements began in the early days of nuclear fission. In 1944, the US Air Force made the first attempts to detect fissiogenic 133Xe in the atmosphere in order to indicate the production of plutonium through the irradiation of uranium and chemical reprocessing in an effort to gather intelligence on the status of the German nuclear program. However, no 133Xe was detected.

There is evidence humans have been processing fish since the early Holocene. For example, fishbones (c. 8140–7550 BP, uncalibrated) at Atlit-Yam, a submerged Neolithic site off Israel, have been analysed. What emerged was a picture of "a pile of fish gutted and processed in a size-dependent manner, and then stored for future consumption or trade. This scenario suggests that technology for fish storage was already available, and that the Atlit-Yam inhabitants could enjoy the economic stability resulting from food storage and trade with mainland sites."

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network